Pharmaceutical News

TCG Labs' Juri Biosciences Secures $210M Deal for EpimAb’s Prostate Cancer Therapy EpimAb Biotherapeutics Juri Biosciences TCG Labs Soleil’s Juri Biosciences secures up to $210M licensing deal with EpimAb Biotherapeutics for a novel T-cell engager targeting metastatic prostate cancer, advancing innovative multispecific antibody therapy.
Novartis Deepens China Ties with Eye Drug Pact Novatis SPHChina Novartis has expanded its strategic collaboration with Shanghai Pharma to promote ophthalmic drugs in China, aiming to enhance market coverage and accelerate growth as it targets a top-three pharma position in the country.
Eli Lilly Acquires SiteOne in $1B Pain Drug Deal Eli Lilly SiteOne Therapeutics Eli Lilly has acquired SiteOne Therapeutics in a deal worth up to $1 billion to develop STC-004, a promising non-opioid NaV1.8 inhibitor for chronic pain, advancing next-gen, addiction-free pain therapies.
FDA Halts Rocket’s Gene Therapy Trial After Fatality FDA Rocket Biotech Rocket Pharmaceuticals faces an FDA clinical hold on its gene therapy trial for Danon disease following a patient death. The company is reassessing its approach and extending its financial runway into 2027.
ASCO 2025: Multiple Domestic New Drugs Reveal Impressive Clinical Data ASCO Market Trend ASCO 2025 highlights impressive clinical data from multiple domestic new drugs including Kelun Biotech's sacituzumab govitecan, Mabwell's 9MW2821, Zelgen Bio's ZG006, and Hengrui's SHR-1501, showing promising efficacy and safety.
ASCO 2025: Innovent, RemeGen, Kelun Showcase Together! ASCO Market Trend ASCO 2025 highlights: Leading Chinese biotech companies Xinda, Rongchang, and Kelun present innovative clinical trial data on ADCs, bispecific antibodies, and targeted therapies, showcasing China's rising role in oncology innovation.
ASCO 2025: Most-Viewed Abstracts ASCO Cancer Oncology Market Trend Discover the top 4 most viewed abstracts at ASCO 2025, including updates on zanidatamab, talazoparib, GFH375, and Ziftomenib across gastric, prostate, solid tumors, and AML research.
ASCO 2025: Top 10 Clinical Breakthrough Oncology Products with Key Trial Results ASCO Cancer Oncology Market Trend Discover the top 10 clinical breakthrough oncology products presented at ASCO 2025, featuring innovative therapies from leading companies with promising efficacy and safety data in advanced cancers.
2025 ASCO: Chinese Pharma Innovations in Lung, Gastric, Blood & Thyroid Cancer Treatments ASCO Cancer Oncology Market Trend 2025 ASCO abstracts highlight breakthroughs by Chinese pharmaceutical companies across lung, gastric, hematologic, and thyroid cancers, showcasing innovation in targeted and combination therapies.
Biotech Cuts Jobs Despite $350M Funding Biotech Eikon Therapeutics Eikon Therapeutics raised $350M in 2025 to advance its drug pipeline, including Chinese-licensed assets, but recently announced a 15% layoff due to reduced U.S. research funding.